Initiation IBT
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
COVID-19 Response Interim Report
JUNE 2021 COVID-19 response interim report Interim Report (January 2020 to March 2021) Medical Research Council Evaluation and Analysis Team I Foreword The intent of this report is to document the main activities undertaken by Medical Research Council (MRC), part of UK Research and Innovation (UKRI), and its community of researchers in response to the SARS-CoV-2 pandemic and to recognise the impacts and insights arising from these activities. As the response and outcomes will continue past 2021, this is an interim report covering January 2020 to March 2021. It is proposed that a final form of this report is produced in 2022. The report is a collection of eight summaries of separate components of the MRC-led aspects of the UKRI COVID-19 response and their impact rather than a connected narrative of events. Highlighted blue and bold text provide links to more detailed descriptions either within the document and the Annexes or external webpages. Methods and acknowledgements The information in this paper has been gathered live throughout 2020. Funding activity data was collated from various off-line call processes by Matt Coles. Activity, outcomes, and impact information from the research community was primarily self-reported in project and Institute, Unit and Centre surveys and Researchfish®. Interviews were undertaken with MRC staff in May and October 2020 and in January 2021. The data was gathered, and the report composed by Emily Gale, Ian Viney, Buddhini Samarasinghe, and James Carter. Additional analysis was provided by the members of the Evaluation and Analysis Team: Joe Murphy and Dominic Hedges. -
Handbook 2015
2015 Handbook genesis 2015 60 years ago, British researchers co-discovered the structure of DNA. Today they continue to make world-changing discoveries. Unlock your global business potential with UK innovation. DNA (deoxyribonucleic acid) molecule gov.uk/ukti sponsors 3 Genesis 2015 Sponsors Contents Gold Sponsors Welcome 6 Keynote Speakers 7 Speaker Profiles 8 - 25 Programme 26 - 27 Floor Plan and Exhibitor List 28 - 29 The Source Lounge 32 Exhibitors 34 - 43 Silver Sponsors Corporate Patron Corporate Sponsors Bronze Sponsors Partners Supporters 60 years ago, British researchers co-discovered the structure of DNA. Today they continue to make world-changing discoveries. Unlock your global business potential with UK innovation. Media Partners DNA (deoxyribonucleic acid) molecule gov.uk/ukti Media Supporters Catalysing the power “Life sciences is the most of the golden triangle exciting and rewarding sector to invest in” Dr Eliot Forster, CEO, Immunocore, and Executive Chair, MedCity From the Francis Crick Institute and the Early-stage life sciences companies offer Cell Therapy Catapult to Imperial West and exciting opportunities for investors to make AstraZeneca’s Global R&D Centre, the life excellent returns and make a difference to sciences constellation of the London-Oxford- the health and well-being of thousands. Cambridge golden triangle is in a period of unprecedented ambition. Angels in MedCity runs regular free workshops for potential investors to understand the sector, Established by the Mayor of London with the identify strong propositions and connect with capital’s three academic health science centres, angel syndicates led by sector experts. MedCity is championing entrepreneurship and investment to build on the region’s global Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. -
Investment Manager Review NAV and Share Price
FACTSHEET — SEPTEMBER 2020 ibtplc.com Investment Manager Review In September 2020, the Trust’s NAV per share returned 7.5%* (GBP) while the NASDAQ Biotechnology Index (NBI) returned 5.3%* (GBP). The FTSE All-Share Index returned -1.7%* (GBP) and the S&P 500 Index returned -0.9%* (GBP). IBT’s share price returned 9.0%* (GBP). Key attributes of the Trust The main positive contributors to NAV in the month were Immunomedics, Myokardia and Horizon Driven by strong fundamentals of the Biotech Therapeutics. The Trust’s NAV benefited following the announcement that Gilead, a top-10 holding, intended sector. to acquire Immunomedics for USD 21bn, representing a 108% premium to the previous day’s closing price. Access to a broad spectrum of quoted and Myokardia’s share price increased following the release of positive phase 3 EXPLORER-HCM clinical trial unquoted investments. results for Mavacamten, a treatment for Obstructive Hypertrophic Cardiomyopathy. Horizon Therapeutics’ share price continues to perform well, driven by strong sales data from their lead asset, Tepezza. Provides investors exposure to both growth and a competitive yield. The main detractors from the NAV in the month were Neurocrine, Halozyme and Regeneron. Neurocrine’s Bottom up stock selection with diversification share price performed poorly during the month. There was no specific event that triggered this performance. overlay. However, Neurocrine’s third quarter sales have historically been weak which may have affected investor Medically and financially experienced Fund sentiment. Halozyme’s share price was negatively affected by the news that Johnson & Johnson had entered Managers with access to specialists at SV into arbitration with Genmab over royalty payment from the injection form of Darzalex.